Phenotypes associated with this allele

• Allele Symbol: Zfyve21^{tm2c(EUCOMM)Wtsi}
• Allele Name: targeted mutation 2c, Wellcome Trust Sanger Institute
• Allele ID: MGI:7709477
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Zfyve21^tm2c(EUCOMM)Wtsi/Zfyve21^tm2c(EUCOMM)Wtsi Tg(Cdh5-cre/ERT2)1Rha/0 Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+	involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6N	MGI:7709530

Genotype
MGI:7709530

cn1

• Allelic Composition: Zfyve21^{tm2c(EUCOMM)Wtsi}/Zfyve21^{tm2c(EUCOMM)Wtsi}; Tg(Cdh5-cre/ERT2)1Rha/0; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

growth/size/body

abnormal body weight ( J:350543 )

• by 3 months of age tamoxifen treated mice show increased organ weight to body weight ratios

decreased body weight ( J:350543 )

• following tamoxifen treatment at P1-P5

• difference in weight increases progressively with age reaching approximately a 40% decrease by 6 months of age

renal/urinary system

abnormal peritubular capillary morphology ( J:350543 )

• decreased junctional density in tamoxifen treated mice, possibly secondary to edema

increased glomerular capsule space ( J:350543 )

• wider spaces at 6 months of age in tamoxifen treated mice

decreased podocyte number ( J:350543 )

• modest decrease in WT-1+ podocyte densities in tamoxifen treated mice

abnormal renal glomerulus morphology ( J:350543 )

• increased glomerular volume in tamoxifen treated mice at 6 months of age

• in tamoxifen treated mice glomerular endothelial cells become swollen and subendothelial thickening is seen

abnormal glomerular endothelium fenestra morphology ( J:350543 )

• glomerular loops show reduced fenestrae in tamoxifen treated mice

abnormal kidney physiology ( J:350543 )

• expression analysis indicates reduced ENOS activity in renal microvasculature from tamoxifen treated mice at 3 months of age

abnormal renal filtration ( J:350543 )

• elevated albumin to creatinine ratio in the urine in tamoxifen treated mice

abnormal glomerular filtration barrier function ( J:350543 )

• progressive, age-related dysfunction in tamoxifen treated mice

decreased renal glomerular filtration rate ( J:350543 )

• in tamoxifen treated mice at 6 months of age

abnormal renal water homeostasis ( J:350543 )

• tubulointerstitial edema in tamoxifen treated mice

homeostasis/metabolism

increased circulating creatinine level ( J:350543 )

• in tamoxifen treated mice

decreased circulating serum albumin level ( J:350543 )

• in tamoxifen treated mice

edema ( J:350543 )

• increased wet weights of multiple tissues, including the kidneys, liver, lung, and heart in tamoxifen treated mice

cardiovascular system

abnormal glomerular endothelium fenestra morphology ( J:350543 )

• glomerular loops show reduced fenestrae in tamoxifen treated mice

abnormal peritubular capillary morphology ( J:350543 )

• decreased junctional density in tamoxifen treated mice, possibly secondary to edema

increased vascular permeability ( J:350543 )

• increased Evans Blue dye extravasation from kidney vessels in tamoxifen treated mice